An Overview of siRNA Delivery Strategies for Urological Cancers

被引:8
作者
Halib, Nadia [1 ]
Pavan, Nicola [2 ]
Trombetta, Carlo [2 ]
Dapas, Barbara [3 ]
Farra, Rossella [3 ]
Scaggiante, Bruna [3 ]
Grassi, Mario [4 ]
Grassi, Gabriele [3 ]
机构
[1] Univ Sains Islam Malaysia, Fac Dent, Dept Basic Sci & Oral Biol, Kuala Lumpur 55100, Malaysia
[2] Univ Trieste, Dept Med Surg & Hlth Sci, Urol Clin, I-34149 Trieste, Italy
[3] Trieste Univ, Cattinara Univ Hosp, Dept Life Sci, Str Fiume 447, I-34149 Trieste, Italy
[4] Trieste Univ, Dept Engn & Architecture, Via Valerio 6, I-34127 Trieste, Italy
关键词
bladder cancer; prostate cancer; renal cancer; siRNA; delivery; PROSTATE-CANCER; IN-VITRO; BLADDER-CANCER; DRUG-DELIVERY; SIOG GUIDELINES; ULTRASONIC DRUG; KINASE; NANOPARTICLES; EXPRESSION; CARCINOMA;
D O I
10.3390/pharmaceutics14040718
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) seems to be of great therapeutic interest. siRNAs are double-stranded RNA molecules which can specifically target virtually any mRNA of pathological genes. For this reason, siRNAs have a great therapeutic potential for human diseases including urological cancers. However, the fragile nature of siRNAs in the biological environment imposes the development of appropriate delivery systems to protect them. Thus, ensuring siRNA reaches its deep tissue target while maintaining structural and functional integrity represents one of the major challenges. To reach this goal, siRNA-based therapies require the development of fine, tailor-made delivery systems. Polymeric nanoparticles, lipid nanoparticles, nanobubbles and magnetic nanoparticles are among nano-delivery systems studied recently to meet this demand. In this review, after an introduction about the main features of urological tumors, we describe siRNA characteristics together with representative delivery systems developed for urology applications; the examples reported are subdivided on the basis of the different delivery materials and on the different urological cancers.
引用
收藏
页数:27
相关论文
共 50 条
[21]   Implications of c-Myc in the pathogenesis and treatment efficacy of urological cancers [J].
Hushmandi, Kiavash ;
Saadat, Seyed Hassan ;
Raei, Mehdi ;
Daneshi, Salman ;
Aref, Amir Reza ;
Nabavi, Noushin ;
Taheriazam, Afshin ;
Hashemi, Mehrdad .
PATHOLOGY RESEARCH AND PRACTICE, 2024, 259
[22]   Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers [J].
Amaro, Filipa ;
Carvalho, Marcia ;
Bastos, Maria de Lourdes ;
de Pinho, Paula Guedes ;
Pinto, Joana .
PHARMACEUTICALS, 2022, 15 (03)
[23]   A review for the impacts of circadian disturbance on urological cancers [J].
Li, Tao ;
Jiang, Yiting ;
Bai, Yunjin ;
Jiang, Kehua ;
Du, Guangshi ;
Chen, Peng ;
Luo, Chao ;
Li, Lei ;
Qiao, Jun ;
Shen, Jun .
SLEEP AND BIOLOGICAL RHYTHMS, 2024, 22 (02) :163-180
[24]   Urinary microbiome and urological cancers: a mini review [J].
Randazzo, Gianmarco ;
Bovolenta, Eleonora ;
Ceccato, Tommaso ;
Reitano, Giuseppe ;
Betto, Giovanni ;
Novara, Giacomo ;
Iafrate, Massimo ;
Morlacco, Alessandro ;
Dal Moro, Fabrizio ;
Zattoni, Fabio .
FRONTIERS IN UROLOGY, 2024, 4
[25]   Matrix Systems for siRNA Delivery [J].
Naeye, B. ;
Raemdonck, K. ;
Remaut, K. ;
Demeester, J. ;
De Smedt, S. C. .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (02) :89-96
[26]   Nanoplatforms for Delivery of siRNA to the Eye [J].
Kataki, Manjir Sarma ;
Kakoti, Bibhuti Bhusan ;
Jameson, Melanie ;
Solanki, Aum ;
Hirani, Anjali ;
Pathak, Yashwant .
CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (31) :4587-4593
[27]   Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation [J].
Peng, Ding ;
Ge, Guangzhe ;
Xu, Zhengzheng ;
Ma, Qin ;
Shi, Yue ;
Zhou, Yuanyuan ;
Gong, Yanqing ;
Xiong, Gengyan ;
Zhang, Cuijian ;
He, Shiming ;
He, Zhisong ;
Li, Xuesong ;
Ci, Weimin ;
Zhou, Liqun .
EPIGENOMICS, 2018, 10 (09) :1189-1199
[28]   Mesenchymal stem cells and their extracellular vesicles in urological cancers: Prostate, bladder, and kidney [J].
Saadh, Mohamed J. ;
Alhuthali, Hayaa M. ;
Anibal, Oblitas Gonzales ;
Asenjo-Alarcon, Jose Ander ;
Younus, Dhuha Ghassan ;
Alhili, Ahmed ;
Adhab, Zainab Hussein ;
Alsalmi, Ohud ;
Gharib, Amal F. ;
Pecho, Renzon Daniel Cosme ;
Akhavan-Sigari, Reza .
CELL BIOLOGY INTERNATIONAL, 2024, 48 (01) :3-19
[29]   Strategies and advances in nanomedicine for targeted siRNA delivery [J].
Nimesh, Surendra ;
Gupta, Nidhi ;
Chandra, Ramesh .
NANOMEDICINE, 2011, 6 (04) :729-746
[30]   GENE-THERAPY IN UROLOGICAL ONCOLOGY - PRINCIPLES, STRATEGIES AND POTENTIAL [J].
BREWSTER, SF ;
SIMONS, JW .
EUROPEAN UROLOGY, 1994, 25 (03) :177-182